SightScore™ for Research
Biomarker for Pharmaceutical Trials & Academic Research
CommercialActive
Key Facts
Indication
Biomarker for Pharmaceutical Trials & Academic Research
Phase
Commercial
Status
Active
Company
About Seonix Bio
Seonix Bio is an early-stage diagnostics company commercializing a polygenic risk score (PRS) test called SightScore™ for predicting genetic risk of glaucoma and age-related macular degeneration (AMD). The company leverages extensive genetic research published in leading journals to provide a clinically relevant tool intended to guide monitoring and management decisions in ophthalmology. Currently available in the US, Australia, and New Zealand as a laboratory-developed test (LDT), Seonix targets both clinical use and research collaborations while navigating the pre-FDA approval regulatory pathway.
View full company profile